575 abstracts found.



Results filter

First Results of COSTAR (CRUK/08/004): A randomised trial of 3-Dimensional Conformal Radiotherapy (3DCRT) vs Cochlea-Sparing Intensity Modulated Radiotherapy (CS-IMRT) in patients with parotid cancer.

Year:

Session type:

Theme:

Christopher Nutting1,James Morden2,Matthew Beasley3,Shree Bhide1,Marie Emson4,Mererid Evans5,Lydia Fresco6,Dorothy Gujral1,Kevin Harrington1,Catherine Lemon7,Rekha Neupane8,Kate Newbold1,Robin Prestwich9,Martin Robinson10,Paul Sanghera11,Muthiah Sivaramalingam12,Mark Sydenham4,Emma Wells1,Steph Witts4,Emma Hall4
1Royal Marsden Hospital,2The Institute of Cancer Research,3Bristol Haematology and Oncology Centre,4Institute of Cancer Research,5Velindre Hospital,6University Hospitals Coventry and Warwickshire NHS Trust,7Mount Vernon Hospital,8Glan Clwyd Hospital,9St James Institute of Oncology,10Sheffield Teaching Hospitals NHS Foundation Trust,11Queen Elizabeth Hospital, Birmingham,12Royal Preston Hospital

The impact of co-morbidities on recovery from colorectal cancer within first 2 years after surgery: results from the UK Colorectal Wellbeing (CREW) cohort study

Year:

Session type:

Theme:

Joanne Haviland1,Amanda Cummings1,Jane Winter1,Chloe Grimmett1,Lynn Calman1,Jessica Corner1,Amy Din1,Deborah Fenlon1,Christine M. May1,Alison Richardson1,Peter W. Smith1,Claire Foster1
1University of Southampton

Surgery for retroperitoneal sarcoma in the elderly

Year:

Session type:

Theme:

Henry Smith1,Joseph Meirion Thomas1,Myles Smith1,Andrew Hayes1,Dirk Strauss1
1The Royal Marsden Hospital

A liver surgeon’s view of colorectal cancer

Year:

Session type:

Theme:

James Garden1
1University of Edinburgh

First Results of ART DECO (CRUK/10/018): a randomised trial of dose escalated intensity modulated radiotherapy (DE-IMRT) versus standard dose IMRT (ST-IMRT) in locally advanced head and neck cancer

Year:

Session type:

Theme:

Christopher Nutting1,James Morden2,Matthew Beasley3,David Bernstein4,Vivian Cosgrove5,Sheila Fisher6,Bernadette Foran7,Teresa Guerro-Urbano8,Dorothy Gujral4,Elizabeth Junor9,Hisham Mehenna10,Nachi Palaniappan11,Shanmugasundaram Ramkumar12,Paul Sanghera13,Mehmet Sen5,Amen Sibtain14,Win Soe15,Catharine West16,Deborah Piercy2,Stephanie Witts2,Marie Emson2,Emma Hall2
1Royal Marsden Hospital,2The Institute of Cancer Research,3University Hospitals Bristol NHS Foundation Trust,4The Royal Marsden NHS Foundation Trust,5The Leeds Teaching Hospitals NHS Trust,6University of Leeds,7Sheffield Teaching Hospitals NHS Foundation Trust,8Guy's and St Thomas' NHS Foundation Trust,9NHS Lothian,10University of Birmingham,11Velindre NHS Trust,12University Hospital Southampton NHS Foundation Trust,13University Hospitals Birmingham NHS Foundation Trust,14Barts Health NHS Trust,15Betsi Cadwaladr University Health Board,16The University of Manchester

ESPAC-4: An international randomized phase-3 trial of adjuvant combination chemotherapy using gemcitabine (GEM) and capecitabine (CAP) versus mono therapy gemcitabine in resected pancreatic cancer

Year:

Session type:

Theme:

John Neoptolemos1,Daniel Palmer2,Paula Ghaneh2,Juan Valle3,David Cunningham4,Jon Wadsley5,Tim Meyer6,Alan Anthoney7,Bengt Glimelius8,Stephen Falk9,Pehr Lind10,Jakob Izbicki11,Gary Middleton12,Paul Ross13,Harpreet Wasan14,Alec McDonald15,Tom Crosby16,Eftychia Psarelli2,Pascal Hammel17,Markus Buchler18
1Cancer Research UK Liverpool Cancer Trials Unit,2University of Liverpool,3The Christie Hospital,4Royal Marsden Hospital,5Weston Park Hospital,6Royal Free Hospital,7St James's University Hospital,8University of Uppsala,9Bristol Haematology and Oncology Centre,10Karolinska University Hospital,11University of Hamburg Medical Institutions UKE,12Royal Surrey County Hospital,13Guy's Hospital, London,14Hammersmith Hospital,15The Beatson West of Scotland Cancer Centre,16Velindre Hospital,17Hopital Beaujon, Clichy,18University of Heidelberg

Multimodality image fusion method for guiding minimally invasive surgery in prostate cancer.

Year:

Session type:

Theme:

Jyothsna Divyananda1,Hu Xu2,Ghulam Nabi2
1University of Dundee,2Division of Cancer Research, NInewells Hospital, University of Dundee

Predictors of post-operative complications following pancreaticoduodenectomy

Year:

Session type:

Theme:

Andrew Nickinson1,Gavin Smith1,Iseult Flynn1,Mohammed Abu-Hilal1,Zaed Hamady1
1University Hospital Southampton

Long term oncologic outcomes following minimally invasive resection for oesophago-gastric cancer.

Year:

Session type:

Theme:

Esther Platt1,Esther Platt1,Deepali Prakash2,Darmarajah Veeramootoo3,Saj Wajed2
1Derriford Hospital NHS Trust,2Royal Devon and Exeter NHS Foundation Trust,3Frimley Health NHS Foundation Trust

Reporting of Outcomes in Gastric Cancer Surgery Trials: A Systematic Review

Year:

Session type:

Theme:

Bilal Alkhaffaf1,Iain Bruce1,Paula Williamson2,Jane Blazeby3,Anne-Marie Glenny4
1Central Manchester University Hospitals NHS Foundation Trust,2University of Liverpool,3University of Bristol,4University of Manchester

TACE 2: A randomized placebo-controlled, double-blinded, phase III trial of sorafenib in combination with transarterial chemoembolisation (TACE) in patients with unresectable hepatocellular carcinoma

Year:

Session type:

Theme:

Tim Meyer1,Richard Fox2,Yuk Ting Ma2,Paul Ross3,Martin James4,Richard Sturgess5,Clive Stubbs2,Lucy Wall6,Anthony Watkinson7,Nigel Hacking8,Jeffry Evans9,Peter Collins10,Richard Hubner11,David Cunningham12,John Primrose13,Philip Johnson14,Daniel Palmer14
1UCL Cancer Institute,2University of Birmingham,3Guy's Hospital,4University of Nottingham,5Aintree University Hosptial,6Western General Hospital,7The Royal Devon and Exeter Hospital,8Southampton University Hospitals NHS Trust,9Beatson West of Scotland Cancer Centre,10Bristol Royal Infirmary,11Christie Hospital NHS Foundation Trust,12Royal Marsden Hospital,13University of Southampton,14University of Liverpool

The use of Oncotype Dx in adjuvant chemotherapy decision-making in early breast cancer patients with intermediate risk of mortality at 10 years

Year:

Session type:

Theme:

Anisha Ramessur1,Catherine Harper-Wynne2,Russell Burcombe2,Rema Joythirmayi2
1MAIDSTONE AND TUNBRIDGE WELLS NHS TRUST,2Maidstone and Tunbridge Wells NHS Trust

Gold nanoparticle radiopharmaceuticals for the selective treatment of telomerase-positive tumours

Year:

Session type:

Theme:

Bas Bavelaar1,Lei Song1,Mark Jackson2,Philip Waghorn3,Katherine Vallis1
1University of Oxford,2University of Glasgow,3Harvard University

Fibroblast growth factor receptor 3 (FGFR3) mutant muscle invasive bladder cancers (MIBC) are associated with low immune infiltrates

Year:

Session type:

Theme:

Elaine Kilgour1,Elaine Kilgour1,Helen K. Angell2,Neil R. Smith3,Miika J. Ahdesmaki2,J. Carl Barrett4,Elizabeth A. Harrington2,Carolyn Hurst5,Margaret Knowles5
1AstraZeneca,2AstraZeneca, Cambridge UK,3AstraZeneca, Macclesfield UK,4AstraZeneca, Boston USA,5Institute of Cancer Studies, Leeds UK

The oncological safety of nipple sparing mastectomy: The European INSPIRE Project

Year:

Session type:

Theme:

Isabel Rubio1
1Hospital Universitario Vall d´Hebron

Oncological safety of lipomodelling in breast cancer

Year:

Session type:

Theme:

Siobhan Laws1
1Royal Hampshire County Hospital

Cancer data management and analysis using a pre-planned multi-database approach across Nordic countries and the United Kingdom

Year:

Session type:

Theme:

Morten Andersen1
1Karolinska Institute

Quality of life results of BIG 02-04 MRC EORTC SUPREMO trial of chest wall radiotherapy in patients with intermediate risk stage II breast cancer after mastectomy

Year:

Session type:

Theme:

Galina Velikova1,Linda Williams2,Sarah Willis3,John Cairns3,Kathleen Riddle4,Susan Hermiston2,Nicola Russell5,Ian Kunkler2
1University of Leeds,2University of Edinburgh, Edinburgh, UK,3London School of Hygiene and Tropical Medicine, London, UK,4Scottish Clinical Trials Research Unit, Edinburgh, UK,5The Netherlands Cancer Institute, Amsterdam, The Netherlands

Two-Year Efficacy and Safety Update: Phase III CheckMate 025 Study of Nivolumab vs Everolimus in Patients With Advanced Renal Cell Carcinoma (aRCC)

Year:

Session type:

Theme:

Elizabeth R. Plimack1,Robert J. Motzer2,Bernard Escudier3,Padmanee Sharma4,David F. McDermott5,Saby George6,Hans J. Hammers7,Michael Carducci7,Scott S. Tykodi8,Jeffrey A. Sosman9,Toni K. Choueiri10,Frede Donskov11,Howard Gurney12,Thomas C. Gauler13,Takeshi Ueda14,Huanyu Zhao15,Elmer Berghorn15,John Wagstaff16
1Fox Chase Cancer Center,2Memorial Sloan Kettering Cancer Center,3Gustave Roussy,4MD Anderson Cancer Center, University of Texas,5Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center,6Roswell Park Cancer Institute,7Johns Hopkins Sidney Kimmel Comprehensive Cancer Center,8University of Washington and Fred Hutchinson Cancer Research Center,9Vanderbilt University Medical Center,10Dana-Farber Cancer Institute/Brigham and Women’s Hospital,11Aarhus University Hospital,12Westmead Hospital and Macquarie University,13University Hospital Essen of University of Duisburg-Essen,14Chiba Cancer Center,15Bristol-Myers Squibb,16South West Wales Cancer Institute and Swansea University College of Medicine

Weekly cisplatin concurrent with IMRT does not increase risk of Lhermitte’s syndrome in head and neck cancer patients

Year:

Session type:

Theme:

Hannah Laidley1,David Noble2,Gill Barnett3,Raj Jena2,Neil Burnet2
1Cambridge University School of Clinical Medicine,2Cancer Research UK VoxTox Research Group, Department of Oncology, University of Cambridge,3Department of Oncology, Cambridge University Hospital's NHS Foundation Trust

BARRETT’S OESOPHAGUS PATIENTS ATTENDING HOSPITAL: BASELINE CLINICAL, PATIENT HISTORY AND QUALITY OF LIFE DATA FROM BOSS AND ASPECT

Year:

Session type:

Theme:

Sharon Love1,Gavin Reilly1,Corran Roberts1,Adelyn Wise2,Paul Moayyedi3,Chris Foy4,Clive Stokes4,John De Caestecker5,Stephen Attwood6,Peter Watson7,Yeng Ang8,Pradeep Bhandiri9,Oliver Old4,Julie Hapeshi4,Ian Penman10,Colin Rodgers11,Cathryn Edwards12,David Monk13,Krish Ragunath14,Danielle Morris15,David Johnston16,Hugh Barr4,Janusz Jankowski17
1Centre for Statistics in Medicine (CSM), University of Oxford,2Oncology Clinical Trials Office, University of Oxford,3Department of Medicine, McMaster University Ontario, Canada,4Gloucester Royal Hospital, Gloucester, United Kingdom,5University Hospital Leicester, Leicester, United Kingdom,6School of Medicine, Pharmacy and Health, Durham University, Durham, United Kingdom,7Queens University Belfast,8Wrightington, Wigan & Leigh NHS, Wigan,9Spire Portsmouth Hospital, Portsmouth,,10Western General Hospital and Royal Infirmary Edinburgh, Edinburgh, United Kingdom,11Northern Trust, Antrim, United Kingdom,12South Devon Healthcare NHS Foundation Trust, Devon, United Kingdom,13Chester Hospital, Chester, United Kingdom,14Nottingham University Hospital, Nottingham, United Kingdom,15Queen Elizabeth II Hospital, Welwyn Garden City, United Kingdom,16Ninewells Hospital, Dundee, United Kingdom,17University Hospitals Coventry & Warwickshire NHS Trust, United Kingdom

Incorporating cancer risk information into general practice: a qualitative study using focus groups with healthcare professionals

Year:

Session type:

Theme:

Juliet Usher-Smith1,Barbora Silarova1,Alison Ward2,Jane Youell2,Kenneth Muir3,Jackie Campbell2,Joanne Warcaba4
1University of Cambridge,2University of Northampton,3University of Manchester,4Moulton Surgery, Northampton

Cervical cancer survival among women referred to cancer centres in Ghana

Year:

Session type:

Theme:

Yvonne Nartey1,Brian Cox1,Philip Hill1,Amo-Kwabena Antwi2
1University of Otago,2Komfo Anokye Teaching Hospital

Why do I choose to get screened? An examination of factors influencing participation in the Scottish Bowel Screening Programme

Year:

Session type:

Theme:

Kirsty Bisset1,Paul G Horgan1,Emilia M Crighton2,David Mansouri1
1Academic Unit of Surgery, School of Medicine - University of Glasgow,2Department of Public Health Screening Unit, NHS Greater Glasgow & Clyde

General practitioner attitudes towards prescribing aspirin to carriers of Lynch Syndrome: findings from a national survey

Year:

Session type:

Theme:

Samuel Smith1,Robbie Foy2,Jennifer McGowan3,Lindsay Kobayashi3,John Burn4,Karen Brown5,Lucy Side3,Jack Cuzick1
1Queen Mary University of London,2University of Leeds,3University College London,4Newcastle University,5University of Leicester

General Practitioner attitudes towards prescribing tamoxifen for the primary prevention of breast cancer: results of a vignette study

Year:

Session type:

Theme:

Samuel Smith1,Robbie Foy2,Jennifer McGowan3,Lindsay Kobayashi3,Karen Brown4,Lucy Side3,Jack Cuzick1
1Queen Mary University of London,2University of Leeds,3University College London,4University of Leicester

The development of GBM – A single case study

Year:

Session type:

Theme:

Astrid Wendler1,Sarah Field1,Juliane Perner1,Simon Tavaré1,Colin Watts1
1Cambridge University

Outcomes for patients diagnosed with metastatic pancreatic ductal adenocarcinoma (mPDAC): a tertiary referral centre experience.

Year:

Session type:

Theme:

Angela Lamarca1,Robert D Morgan1,Christina Rigby1,Rille Pihlak2,Lynne McCallum1,Mairéad G McNamara2,Juan W Valle2,Richard A Hubner1
1Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom,2Department of Medical Oncology, The Christie NHS Foundation Trust; Institute of Cancer Sciences, Manchester Academic Health Science Centre, University of Manchester, United Kingdom

Statin use is associated with lower pro-tumourigenic (M2) macrophage number in the microenvironment of in situ versus invasive lung adenocarcinoma

Year:

Session type:

Theme:

Esraa Aldujaily1,Tamihiro Kamata2,David Moore3,Catrin Pritchard4,John LeQuesne5
1University of Leicester,2Department of Molecular Cell Biology, University of Leicester, UK,3Department of Cancer Studies, University of Leicester, UK,4Department of Cancer Studies, University of Leicester, UK; Department of Molecular Cell Biology, University of Leicester, UK,5MRC Toxicology Unit, Leicester, UK

Investigation of the Role of Alcohol in Colorectal Tumour Development in Mouse Models

Year:

Session type:

Theme:

Mike Mueller1,Ying Zhou1,Mark J Arends1
1Edinburgh Cancer Research Centre

Understanding ethnic disparities in uptake of HPV vaccination in England: A comparative qualitative study

Year:

Session type:

Theme:

Alice Forster1,Lauren Rockliffe1,Laura Marlow1,Emily McBride1,Jo Waller1
1UCL

Is socio-economic status relevant in HPV oropharyngeal cancer?

Year:

Session type:

Theme:

Yinan Zhu1,Athena Togo2,Rohit Gohil2,Richard Oparka2,Jaiganesh Manickavasagam2
1University of Dundee,2NHS Tayside

The PrEvENT Feasibility Trial – Results of the Qualitative Feasibility Analysis

Year:

Session type:

Theme:

Ellie Shingler1,Luke Robles1,Lucy Hackshaw-McGeagh1,Raj Persad2,Anthony Koupparis2,Edward Rowe2,Constance Shiridzinomwa3,Amit Bahl4,Richard M Martin5,J Athene Lane5
1NIHR Biomedical Research Unit in Diet, Nutrition and Lifestyle,2Bristol Urological Institute,3North Bristol NHS Trust,4Bristol Haematology & Oncology Centre,5University of Bristol

Bladder cancer risk is associated with low serum 25-hydroxyvitamin D levels; a systematic review

Year:

Session type:

Theme:

Corina Chivu1,Janet Dunn1,Bland Rosemary1,Kieran Jefferson2,Donald MacDonald2,Gulnaz Iqbal1
1University of Warwick,2Department of Urology, University Hospital Coventry and Warwickshire, Coventry

Prostate cancer meta-analysis from more than 143,000 men identifies 57 novel prostate cancer susceptibility loci

Year:

Session type:

Theme:

Rosalind Eeles1,Fredrick R Schumacher2,Ali Amin Al Olama3,Sonja I Berndt4,Fredrik Wilklund5,David V Conti6,Mahbubl Ahmed1,Sara Benlloch7,Douglas F Easton8,Peter Kraft9,Stephen J Chanock4,Brian E Henderson (deceased)6,Zsofia Kote-Jarai1,Christopher A Haiman6
1The Institute of Cancer Research,2Case Western Reserve University,3Cambridge Medical School,4National Cancer Institute,5Karolinkska Institute,6University of Southern California,7PRACTICAL Study, Cambridge Medical School,8Centre for Cancer Genetics Epidemiology,9Harvard School of Public Health

Forecasting the cancer population in the UK to 2040

Year:

Session type:

Theme:

Samuel Jones1,Hannah McConnell1,James Charnock2,Martina Buoni1
1Macmillan Cancer Support,2Macmillan Cancer Support/National Cancer Registration and Analysis Service (NCRAS), Public Health England

Latest Feasibility Outcomes from the Prostate cancer Evaluation of Exercise and Nutrition Trial (PrEvENT)

Year:

Session type:

Theme:

Luke Robles1,Eleanor Shingler1,Lucy Hackshaw-McGeagh1,Raj Persad2,David Gillatt2,Jeff Holly3,Anthony Koupparis2,Edward Rowe2,Lyndsey Johnson4,Jenny Cloete4,Constance Shiridzinomwa4,Paul Abrams2,Chris Penfold1,Amit Bahl2,Jon Oxley5,Claire Perks3,Richard Martin6,Athene Lane6
1NIHR Biomedical Research Unit in Nutrition, Diet and Lifestyle, University of Bristol,2Bristol Urological Institute, North Bristol NHS Trust, Southmead Hospital, Bristol,3School of Clinical Sciences, University of Bristol, Southmead Hospital, Bristol,4North Bristol NHS Trust, Southmead Hospital, Bristol,5Cellular Pathology, North Bristol NHS Trust, Southmead Hospital, Bristol,6School of Social and Community Medicine, University of Bristol

Targeting thioredoxin reductase in pancreatic cancer

Year:

Session type:

Theme:

Khaled Alhadyan1,Stewart G. Martin2,Sarah J. Storr2,Martyn Inman3,Abed M. Zaitoun4,Dileep Lobo5,Chris Moody3
1,2Academic Unit of Clinical Oncology, University of Nottingham, School of Medicine, Nottingham University Hospitals NHS Trust, City Hospital Campus, Nottingham,3School of Chemistry, University of Nottingham,4Department of Pathology, Nottingham University Hospitals, Queen’s Medical Centre, Nottingham,5Division of Gastrointestinal Surgery, University of Nottingham, Nottingham Digestive Diseases Centre National Institute of Health Research Biomedical Research Unit, Nottingham

Evaluation of biomarkers in the UK phase III VorteX trial confirms importance of tumour hypoxia in soft tissue sarcoma

Year:

Session type:

Theme:

Laura Forker1,Piers Gaunt2,Stefano Sioletic3,Patrick Shenjere4,Joely Irlam1,Helen Valentine1,David Hughes5,Ana Hughes2,Lucinda Billingham2,Martin Robinson6,Catharine West1
1University of Manchester,2Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham,3University Hospital of Udine,4Christie Hospital NHS Foundation Trust,5Sheffield Teaching Hospitals NHS Trust,6University of Sheffield

Does pegfilgrastim reduce the incidence of neutropenic sepsis?

Year:

Session type:

Theme:

Rachel Nirsimloo1,David Cameron2,Jacqueline Grove1
1Edinburgh Cancer Centre,2University of Edinburgh

In the era of conservative surgery, can patients presenting with node positive breast cancer be spared axillary node dissection post neoadjuvant chemotherapy? A meta-analysis and review of literature

Year:

Session type:

Theme:

Hiba El Hage Chehade1,Hannah Headon2,Omar El Tokhy2,Umar Wazir2,Jennifer Heeney2,Abdul Kasem2,Kefah Mokbel2
1The Princess Grace Hospital,2The London Breast Institute, The Princess Grace Hospital

Views on provision of personalised cancer risk information: a qualitative interview study with members of the public

Year:

Session type:

Theme:

Juliet Usher-Smith1,Barbora Silarova1,Artitaya Lophatananon2,Robbie Duschinsky1,Jackie Campbell3,Joanne Warcaba4,Kenneth Muir2
1University of Cambridge,2University of Manchester,3University of Northampton,4Moulton Surgery

Routes to prostate cancer progression and identification of new drug targets: results from the CRUK-ICGC prostate initiative

Year:

Session type:

Theme:

Rosalind Eeles1,David Wedge2,Gunes Gundem2,Thomas Mitchell2,Mohammed Ghori2,Adam Butler2,Hayley Whitaker3,Zsofia Kote-Jarai1,Charlie Massie4,Ludmil B. Alexandrov3,Anne Y. Warren5,Clare Verrill6,Dan Berney7,Nening Dennis1,Susan Merson1,Chris Sander8,Freddie C. Hamdy9,Ultan McDermott2,Bissan Al-Lazikani1,Paul Workman1,Andy G. Lynch3,G. Steven Bova10,Christopher S. Foster11,Daniel S. Brewer12,David Neal2,Colin Cooper12
1The Institute of Cancer Research,2Wellcome Trust Sanger Institute,3Cancer Research UK, Cambridge Institute,4University of Cambridge,5Cambridge University Hospitals NHS Foundation Trust,6Oxford University,7Barts Cancer Centre, Barts and the London School of Medicine & Dentistry,8Dana Farber Cancer Institute & Harvard Medical School,9University of Oxford,10University of Tampere, BioMediTech,11HCA Healthcare,12The University of East Anglia

High-dose treatment with ADXS11-001, a Listeria monocytogenes-listeriolysin O (Lm-LLO) immunotherapy, in women with cervical cancer: a phase I, dose-escalation study

Year:

Session type:

Theme:

Sharad Ghamande1,Tom Hare2,Donna Wheatley1,Lisa Hatch1,Bunja Rungruang1,John Janik1,Samir Khleif1
1Georgia Cancer Center, Augusta University,2Advaxis, Inc.

The role of sentinel lymph node biopsy in patients with ductal carcinoma in situ. An updated meta-analysis involving 9803 patients

Year:

Session type:

Theme:

Hiba El Hage Chehade1,Hannah Headon1,Umar Wazir1,Abdul Kasem1,Kefah Mokbel1
1The Princess Grace Hospital

Which patients with locally advanced pancreatic cancer should we be selecting for chemoradiotherapy?

Year:

Session type:

Theme:

Sophie Otter1,Ria Kalaitzaki2,Irene Chong2,Diana Tait2
1Royal Surrey County Hospital,2Royal Marsden Hospital

Circulating cell-free DNA copy-number profiles as a biomarker in melanoma

Year:

Session type:

Theme:

Shobha Silva1,Dawn Teare2,James Bradford2,Ian Brock2,Daniel Connley2,Emilie Jarratt3,Helen Cramp2,Fiona Taylor4,Angela Cox2,Sarah Danson1
1Weston Park Hospital/University of Sheffield,2University of Sheffield,3Sheffield Children's Hospital,4Weston Park Hospital, Sheffield

Modelling the Emergence of Resistance to Chemotherapeutics with Virtual Tumour

Year:

Session type:

Theme:

Frances Brightman1,Eric Fernandez1,David Orrell1,Christophe Chassganole1
1Physiomics plc

NOVEL SERUM CIRCULATING MIRNAS SIGNATURES FOR NSCLC TREATMENT OUTCOME

Year:

Session type:

Theme:

Julija Fadejeva1,Diana Schveigert2,Saulius Cicenas2,Kestutis Suziedelis1
1National Cancer Institute; Faculty of Natural Sciences, Vilnius University Joint Life Sciences Center,2National Cancer Institute

Percentage change in mean corpuscular volume (MCV) and survival in patients with advanced renal cell carcinoma receiving sunitinib

Year:

Session type:

Theme:

Chern Choy1,Martin Highley2
1Peninsula College of Medicine and Dentistry, UK,2Plymouth Oncology Centre, Derriford Hospital, Plymouth, UK